Pipeline/Trials

Our commitment to excellence

Taking on the challenges inherent in today’s cancer treatments isn’t easy…but we’re up for it. We are Athenex—a team of scientists, investigators, and innovators driven by the patients we serve. Our robust investigational pipeline of novel small molecule, biologic, and cellular therapies is focused on both improving outcomes and improving the cancer treatment experience for patients around the world.

Program

Drug candidate

Indication

Pre-clinical

Phase 1

Phase 2

Phase 3

Orascovery

Metastatic breast cancer

Angiosarcoma

Oral paclitaxel + encequidar with dostarlimab**

Neoadjuvant breast cancer
(I-SPY 2)

Oral topotecan + encequidar

Solid tumors

Oral eribulin + encequidar

Solid tumors

Src Kinase Inhibition

Tirbanibulin ointment

Actinic keratosis

TCR-T Immunotherapy

TCRT-ESO-A2

Multiple tumors

Arginase Deprivation Therapy

PT01

Multiple tumors

Posted pipeline was current on March 1, 2021. Pipeline may not reflect changes in phase of development after March 1, 2021.

* Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
** Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline.
*** Collaboration with Eli Lilly and Company, makers of ramucirumab.

Clinical Platform

Orascovery

Oral paclitaxel + encequidar*


Metastatic breast cancer

PHASE 3
(RECEIVED CRL FROM FDA)

Angiosarcoma

PHASE 2

Oral paclitaxel + encequidar with dostarlimab**


Neoadjuvant breast cancer
(I-SPY 2)

PHASE 2
PHASE 1
PHASE 1

Oral topotecan + encequidar


Solid tumors

PHASE 1

Oral eribulin + encequidar


Solid tumors

PHASE 1

Clinical Platform

Src Kinase Inhibition

Tirbanibulin ointment


Actinic keratosis

PHASE 3
(FDA APPROVED)

Clinical Platform

TCR-T Immunotherapy

TCRT-ESO-A2


Multiple tumors

PHASE 1

Clinical Platform

Arginase Deprivation Therapy

PT01


Multiple tumors

PRE-CLINICAL

Posted pipeline was current on March 1, 2021. Pipeline may not reflect changes in phase of development after March 1, 2021.

* Encequidar is the international nonproprietary name (INN) for HM30181A, our novel P-gp pump inhibitor molecule.
** Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline.
*** Collaboration with Eli Lilly and Company, makers of ramucirumab.